Related Experiment Video

Updated: Aug 9, 2026

Bilayer Microfluidic Device for Combinatorial Plug Production
07:03

Bilayer Microfluidic Device for Combinatorial Plug Production

Published on: December 1, 2023

Primer on integrative oncology

Lawrence B Berk1

  • 1Newark Radiation Oncology, 115 McMillen Drive, Newark, OH 43055, USA. lbberk@cancertherapy.us

Hematology/Oncology Clinics of North America
|April 4, 2006
PubMed

Insights

Designing studies for integrative cancer medicine faces challenges. Oncologists need to guide patients toward evidence-based complementary therapies when conventional treatments are insufficient.

Area of Science:

  • Oncology
  • Integrative Medicine
  • Cancer Research

Background:

  • Integrative medicine offers complementary therapies for cancer patients.
  • Standard cancer treatments can be insufficient, leading patients to seek alternatives.
  • Current research faces significant design difficulties in evaluating these techniques.

Purpose of the Study:

  • To highlight the challenges in designing clinical trials for integrative cancer medicine.
  • To emphasize the need for oncologists to understand and guide patients on alternative treatments.

Main Methods:

  • This study reviews the current challenges in designing clinical trials for integrative cancer techniques.
  • It analyzes the reasons for patient inclination towards alternative therapies.

Main Results:

  • There are significant design difficulties in evaluating integrative cancer medicine efficacy.
  • Patients increasingly seek alternative treatments when standard care fails.

Conclusions:

  • Overcoming design challenges is crucial for determining the efficacy of integrative cancer techniques.
  • Oncologists must be knowledgeable about alternative medical agents and techniques to guide patients effectively.

More Related Videos

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...